Greenberg Traurig shareholders Bob Grossman and Josh Samek, along with ex-partner Ira Rosner (now with Holland & Knight), led an 11-attorney team that guided OPKO Health Inc. in its $1.47 billion acquisition in August 2015 of Bio-Reference Laboratories, one of the largest and fastest growing full service diagnostic laboratory companies on the globe. In the all-stock deal, Bio-Reference shareholders received 2.75 shares of OPKO common stock for each share of Bio-Reference common stock. Both firms are publicly traded.
When the sale was announced, OPKO Chairman and CEO Phillip Frost said Bio-Reference's national infrastructure, reach and extensive payer network will be invaluable for the company's physicians and patients across the country.
"We had to work under a very tight timeline," Grossman said. "The last day was an all-nighter. I think we finished at 5 a.m. or something like that."